Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK ALK L1256F |
| Therapy | Alectinib |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK ALK L1256F | lung adenocarcinoma | sensitive | Alectinib | Preclinical - Cell culture | Actionable | In a preclinical study, Alecensa (alectinib) inhibited Alk kinase activity and proliferation of lung adenocarcinoma cells expressing ALK L1256F in the context of EML4-ALK in cell culture (PMID: 30662002). | 30662002 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (30662002) | Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. | Full reference... |